Author: Leblanc, Thierry ; Dourthe, Marie Emilie ; Rigaud, Charlotte ; Ducou Le Pointe, Hubert ; Minard-Colin, Véronique ; Boudjemaa, Sabah ; Simonin, Mathieu ; Landman-Parker, Judith ; Jo Molina, Thierry ; Montravers, Françoise ; Garnier, Nathalie ; Haouy, Stéphanie

Nodular Lymphocyte predominant Hodgkin lymphoma (NLPHL) are rare lymphomas in pediatric patients comprising less than 10 % of all Hodgkin lymphoma (HL). They are for the most part diagnosed at stage I or II and indolent with lymphadenopathy often preceding the diagnosis by many months/years. Survival is excellent. Historically, patients were treated according to classical HL protocols. Due to high toxicity and excellent prognosis, management of NLPHL shifted to de-escalation protocol with good results. No treatment beyond surgical resection was proposed for localized unique nodal disease completely resected. The closed European protocol (EuroNet PHL LP1) evaluated the efficacy of low intensity chemotherapy protocol based on CVP courses (cyclophosphamide vinblastine prednisone) for stage IA/IIA not fully resected. Final results are not yet available. Advanced stage NLPHL are rare and there is no clinical trial and no consensus treatment in children. The SFCE lymphoma committee recently established recommendations for staging and treatment of limited and advanced NLPHL in children based on current practices and published results. The goal was to allow homogeneous practice on a national scale. If incomplete resection for patients with stage I/IIA combination of low intensity chemotherapy (CVP) and rituximab is recommended. For intermediary and advanced stage intensification with AVD (adriamycine vinblastine dacarbazine) or CHOP courses (cyclophosphamide doxorubicine vincristine prednisone) combined with rituximab are advocated. In children, there is no indication for first-line local treatment with radiotherapy.

01 Jul 2013·European Journal of DermatologyQ4 · MEDICINE

Understanding recurrent herpes labialis management and impact on patients’ quality of life: the HERPESCOPE study

Q4 · MEDICINE

Article

Author: Dreno, Brigitte ; Malkin, Jean-Elie ; Saiag, Philippe

Herpes labialis (HL) is a common and benign disease. However, frequent episodes can impair quality of life (QoL) and impact healthcare consumption. The aim of this survey was to understand patients' profiles, behavior, treatment and quality of life, using web-based questionnaires administered in the USA and in France. A total of 1002 and 1005 patients completed it, respectively. Self-diagnosis of HL is usually made at the very start of the prodromal phase. In the USA, 41% of patients seek medical advice at some point and they are often prescribed a topical antiviral drug (AVD) associated with an over-the-counter drug. Those who treat HL by themselves purchase mainly non-antiviral topical drugs. In France, the treatment is almost identical (topical AVD) whether patients seek medical advice (32%) or not. In both countries, patients with 6 or more annual episodes often go to the doctor and use systemic AVD. Continuous treatment is prescribed to 55% and 35% of patients with at least 4 annual episodes, in the USA and France respectively. Sick leaves are delivered to 33% and 14% of patients, respectively. QoL is significantly impaired in a majority of patients, all the more so when HL episodes are more frequent.

01 Aug 1988·International journal of clinical pharmacology, therapy, and toxicology

Central nervous system side effects of antiviral drugs.

Review

Author: Longo, V ; Del Favero, A ; Francisci, D ; Ricci, S

The use of antiviral drugs (AVD) has greatly expanded in the last few years, and these drugs are frequently used in patients with impaired functions and barriers, and therefore a higher risk of adverse effects. However, it is difficult to ascribe with certainty to these drugs CNS symptoms which can be caused by the viral disease itself. In this paper, we reviewed the available informations on CNS side effects of commonly used AVD. No large case-control or cohort study has been published and most informations come from single case reports or short series, in which the neurological symptoms have not been fully described. It is concluded that ad hoc studies are urgently needed to exactly know the extent of the problem and it is suggested that physicians should be prepared to recognize and carefully describe the early manifestations of AVD neurological toxicity.

100 Deals associated with AVD-801

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neurodegenerative Diseases	Preclinical	US	Aviceda Therapeutics, Inc.Startup	-
Neurogenic Inflammation	Preclinical	US	Aviceda Therapeutics, Inc.Startup	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

AVD-801

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation